New ‘Trojan horse’ cancer treatment shows early promise

UK – New ‘Trojan horse’ cancer treatment shows early promise

The innovative new drug, called tisotumab vedotin (TV), releases a toxic substance to kill cancer cells from within. The results have been so positive...
NCCN: Updated NSCLC Guidelines Hone in on PD-L1 Testing

UK – Mapping of oesophageal cancer gene mutations leads to new drug targets

The news, which was published in Nature Genetics, comes from Cancer Research UK researchers at the University of Cambridge, who used whole genome sequencing and...
Lilly CEO on future cancer deals, gene therapy and CAR T-cells

USA – Lilly CEO on future cancer deals, gene therapy and CAR T-cells

Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but...
NCCN: Updated NSCLC Guidelines Hone in on PD-L1 Testing

UK – Immunotherapy extends the life of head and neck cancer patients

The study, by The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, found that the drug – MSD’s Keytruda (pembrolizumab) -...
How Can Nanotechnologies Aid Implantable Drug-Delivery Systems?

International – How Can Nanotechnologies Aid Implantable Drug-Delivery Systems?

Implantable technologies have come a long way over the years, and advancements in micro and nanotechnologies have helped device developers continue to push the...
‘Reprogrammed’ stem cells implanted into patient with Parkinson’s disease

International – ‘Reprogrammed’ stem cells implanted into patient with Parkinson’s disease

Japanese neurosurgeons have implanted ‘reprogrammed’ stem cells into the brain of a patient with Parkinson’s disease for the first time. The condition is only the...
Immunotherapy improves survival in patients with metastatic breast cancer

Immunotherapy improves survival in patients with metastatic breast cancer

An immunotherapy-chemotherapy combination improved both progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic triple-negative breast cancer (TNBC), according to a...
Immuno-Oncology: What’s Next for Pharma?

International – Immuno-Oncology: What’s Next for Pharma?

Immuno-oncology represents a paradigm shift in cancer treatment, with the first wave of PD-1/PD-L1 checkpoint inhibitors such as Opdivo (nivolumab, from Bristol-Myers Squibb Co.)...
Study: Prenatal gene editing treats congenital disease in mice

USA – Study: Prenatal gene editing treats congenital disease in mice

Prenatal gene editing prevented a lethal metabolic disorder in laboratory mice, suggesting it could be possible to treat congential diseases before a child is...

NOS PROCHAINES FORMATIONS